source
- Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancerSolstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round. The funding will support development of its lead candidate, a CTL…
- Luma Group closes $410 million, 15-year life-science venture fundLuma Group announced that its first life‑science venture capital fund has reached final close, raising $410 million for a 15‑year investment period. The New York‑based firm said the capital will be…